SAM enters May with a compound problem: a stock down 13% in a month, options traders at near-peak defensive positioning, and every analyst on the Street still holding neutral but trimming targets in the wake of a bruising first-quarter earnings miss.
The clearest measure of sentiment right now is in options. Traders have moved sharply toward downside protection since the Q1 print on April 30. The put/call ratio hit 1.98 on Tuesday, just a whisker below its 52-week high of 2.09 reached the day before — and 1.73 standard deviations above the 20-day mean of 1.55. That is not a normal level of hedging. The RSI sits at 28.6, deep in oversold territory, which tells you the selling has been sustained rather than a single-day flush. The stock closed at $206.25 on Tuesday, down 13.4% on the week and 14.4% on the month.
The short-interest picture reinforces the defensive read, though without the extremism some might expect at this price level. SI now runs at 12.5% of the free float — meaningful, and up around 7% over the past month as new shorts were added ahead of and following earnings. The week-on-week change is essentially flat, suggesting the build-up paused rather than accelerated after the post-results drop. Borrowing costs are cheap at 0.41%, down sharply from around 0.52% a month ago, which means financing a short position costs next to nothing. Availability remains wide, so there is no imminent squeeze pressure from the lending market. The ORTEX short score of 57.8 is firmly in bearish territory but not extreme — shorts are positioned, not panicked.
The Street's reaction to April 30 results was uniform in direction but measured in tone. Morgan Stanley, Bernstein, Citi, UBS, RBC, and Evercore all cut targets this week, though none changed their ratings — all sitting at Neutral, Equal-Weight, Market Perform, or equivalent. The mean target now stands at $230, implying roughly 12% upside from current levels. That gap between where the stock is and where analysts are anchored is notable: targets were nudged down but the Street is clearly struggling to find conviction in either direction. The bull case rests on the Q1 gross margin print of 48.3% — a five-year high — and signs that Twisted Tea could reaccelerate. The bear case is simpler: elevated advertising spend and structural shortfall fees from Truly production commitments remain a drag, and volume pressure in a tough consumer environment is not easily resolved by margin management alone. EPS momentum factor scores of 25 (30-day) and 21 (90-day) capture how badly estimate revisions have gone — both sit in the bottom quarter of the universe.
The earnings history sharpens the stakes. The April 30 print sent SAM down 9.4% the following session. The prior report in February caused a more modest 2.9% one-day move, though the stock recovered that within a week. Two consecutive quarters of post-earnings selling underlines that the market is holding management to a high bar — investors are punishing any miss immediately. The next event is pencilled in for July 28, giving the market roughly 11 weeks to decide whether the margin story holds or the volume headwinds deepen.
TAP, the closest comparable among peers, managed a 3.6% single-session gain Tuesday against SAM's flat performance, though TAP is also down on the week at -0.9%. BF.B bounced 6.5% on the day, partly on broader staples relief. The relative underperformance of SAM signals the earnings overhang is stock-specific, not a sector-wide drag.
Positioning looks cautious but not capitulatory: options are near peak defensiveness, shorts are comfortable at low borrowing costs, and the analyst community has reset targets lower without stepping up with conviction buys. What to watch heading into Q2 is whether Twisted Tea volume data — the one brand still growing — holds up enough to stabilise estimate revisions before the July print.
See the live data behind this article on ORTEX.
Open SAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
